Authors
Latest:
Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast CancerJulie Gralow, MD, discusses the primary analysis of trastuzumab emtansine plus pertuzumab versus trastuzumab, pertuzumab, and taxane, after anthracyclines as adjuvant therapy in patients with high-risk HER2-positive early breast cancer in the of the KAITLIN study.
Latest:
Targeted/Chemo Combo Effective in Preclinical pNETs StudyCombining the chemotherapy streptozotocin with various mTOR inhibitors was found to effectively target tumors in preclinical studies for pancreatic neuroendocrine tumors (pNETs).
Latest:
Rationale for Genetic Testing in Patients With DLBCLJulie M. Vose, MD, MBA, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma to better understand their disease and treat the disease properly.
Latest:
Getting Genetic Testing to Those Who Need ItJulie Nangia, MD, assistant professor of Medicine, Baylor College of Medicine, discusses getting genetic testing for patients. While the NCCN has guidelines of who should be tested, it may also be possible for physicians to write a letter of medical necessity for other people, such as Ashkenazi Jewish women, who have higher rates of BRCA mutations.
Latest:
Sequencing Immunotherapy in Biomarker-Driven Advanced NSCLCJulie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.
Latest:
Future Research Into Bisphosphonates in Breast CancerJulie R. Gralow, MD, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Care Center, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.
Latest:
GEOMETRY Study Confirms Importance of Testing for METex14 Alterations in Advanced NSCLCJurgen Wolf, MD, discusses the importance of broad genomic testing to identify alterations in patients with advanced non–small cell lung cancer (NSCLC). By identifying molecular alterations and driver mutations early on, patients can receive matched targeted therapies at a time in the course of disease when the treatments would have the greatest impact.
Latest:
Checkpoint Inhibitors Advance Standard of Care for Non-Small Cell Lung CancerJustin F. Gainor, MD, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with non—small cell lung cancer.
Latest:
Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell LeukemiaJustin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
NSCLC: Selecting a Frontline ALK-Targeted TKI TherapyA panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.
Latest:
Expert Addresses Sequencing Challenges in HCCKabir Mody, MD, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma.
Latest:
Advances Changing the Treatment Landscape of AMLKamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia. After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.
Latest:
Researchers Analyze Karyotype Complexity and Prognosis in Acute Myeloid LeukemiaDiagnosis of acute myeloid leukemia (AML) is pivoted around cytogenetic analysis of patient bone marrow or peripheral blood cultures. The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues is based on cytogenetic features along with other clinical, morphological, and immunophenotypic characteristics.
Latest:
Age-Related Recommendations in CLL TherapyWhen treatment decisions are being made regarding chronic lymphocytic leukemia (CLL), patient age should be an important factor. CLL is a disease of the elderly, with more than 40% of all patients >75 years.
Latest:
CLL in the Era of Targeted TherapiesOver the past few years, remarkable advances have been achieved in the field of CLL by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process.
Latest:
Treatment Sequencing in Metastatic Colorectal CancerAn expert breaks down therapy sequencing in metastatic colorectal cancer and provides some clinical pearls.
Latest:
Limitations With Standard of Care in ICI-Pretreated Patients With NSCLCKaren L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.
Latest:
Lung-MAP Trial of Pembrolizumab Plus Ramucirumab Improves Overall Survival in NSCLCKaren L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.
Latest:
Takeaways From Lung-MAP Substudy S1800A in NSCLCKaren L. Reckamp, MD, MS, discusses findings from the phase 2 Lung-MAP substudy S1800A of pembrolizumab and ramucirumab in patients with stage IV, previously-treated non–small cell lung cancer.
Latest:
Toxicities Associated With Talazoparib/Enzalutamide in HRR-Mutant mCRPCKarim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.
